Early phase I/II trials of responder-derived fecal microbiota transplantation in ICI-refractory melanoma achieved objective response rates of 20–40%, while pilot high-fiber or plant-forward dietary interventions improved immunologic surrogates such as CD8+ tumor infiltration. The gene discussed is CD8A; the disease is melanoma.